The
Shuman Law Firm announces that it is investigating potential claims
against certain officers and directors of Retrophin, Inc. (“Retrophin”
or the “Company”) (Nasdaq: RTRX).
Retrophin is a New York, NY-based company that develops therapies for
the treatment of serious, catastrophic or rare diseases.
The Firm’s investigation relates to allegations raised in a federal
lawsuit which claim that three top Retrophin officers either were fired
or stepped down, culminating with the Company's September 30, 2014
announcement that Chief Executive Officer Martin Shkreli was terminated
for allegedly engaging in stock irregularities that included granting
Retrophin stock outside an approved distribution plan. The complaint
also alleges that the defendants caused Retrophin to issue a series of
press releases and U.S. Securities and Exchange Commission filings that
failed to disclose Mr. Shkreli’s stock activity, which allegedly
constitutes a violation of Nasdaq listing rules, state and federal law.
If you currently own Retrophin common stock and are interested in
discussing your rights, or have information relating to this
investigation, please contact Kip B. Shuman or Rusty E. Glenn toll-free
at (866) 569-4531or email Mr. Shuman at kip@shumanlawfirm.com
or email Mr. Glenn at rusty@shumanlawfirm.com.
The Shuman Law Firm represents investors throughout the nation,
concentrating its practice in stockholder litigation.
Copyright Business Wire 2015